Carbidopa (monohydrate)

Carbidopa ((S) - (-) -Carbidopa) monohydrate, a peripheral decarboxylase inhibitor, can be used for the research of Parkinson's disease. Carbidopa monohydrate is a selective aryl hydrocarbon receptor (AhR) modulator. Carbidopa monohydrate inhibits pancreatic cancer cell and tumor growth[1][2].

Product Specifications

CAS Number

[38821-49-7]

Product Name Alternative

(S) - (-) -Carbidopa (monohydrate)

UNSPSC

12352005

Hazard Statement

H302, H319

Target

Aryl Hydrocarbon Receptor

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/carbidopa-monohydrate.html

Purity

98.0

Solubility

DMSO : 20 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

OC1=C(O)C=CC(C[C@](C)(NN)C(O)=O)=C1.O

Molecular Formula

C10H16N2O5

Molecular Weight

244.24

Precautions

H302, H319

References & Citations

[1]Safe S. Carbidopa: a selective Ah receptor modulator (SAhRM) . Biochem J. 2017;474 (22) :3763-3765. Published 2017 Nov 6.|[2]Fermaglich J. Treatment of Parkinson's disease with carbidopa, a peripheral decarboxylase inhibitor, and levodopa. Med Ann Dist Columbia. 1974;43 (12) :587-591.|[3]Gilbert JA, et al. The aromatic-L-amino acid decarboxylase inhibitor carbidopa is selectively cytotoxic to human pulmonary carcinoid and small cell lung carcinoma cells. Clin Cancer Res. 2000;6 (11) :4365-4372.